ResMed Inc. (RMD)
NYSE · San Diego, California, USA · Founded 1989 · CEO Mick Farrell
Valuation summary
$179.91 fair value versus $236.88 in the market, a difference of -24.1%. Rated Reduce.
| Fair value per share | $179.91 |
| Current share price | $236.88 |
| Upside / downside | -24.1% |
| Bear case | $120.92 |
| Bull case | $264.92 |
| Discount rate (WACC) | 8.9% |
| Terminal growth | 2.80% |
| Market capitalisation | $33B |
| EV / Sales | 5.9x |
About ResMed Inc.
Founded in 1989 in Australia by Peter Farrell to commercialise a treatment for sleep apnoea invented at the University of Sydney. His son Mick Farrell has been chief executive since 2013. ResMed makes the machines and masks that keep a sleeper's airway open with gentle air pressure, and is the world leader after its main rival Philips was forced to recall its devices. It also sells software used by home-care providers.
Investment case
- Hundreds of millions of people have untreated sleep apnoea.
- Masks need regular replacement, which makes revenue recurring.
- High margins and no net debt.
Key risks
- Weight-loss drugs reduce sleep apnoea in some patients, which worries investors.
- Philips is returning to the market outside the United States.
- Depends on insurance reimbursement rules.
Revenue by segment
| Sleep and breathing devices | 52% |
| Masks and accessories | 36% |
| Residential care software | 12% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $6.1B | $1.1B |
| Year 2 | $6.7B | $1.2B |
| Year 3 | $7.3B | $1.3B |
| Year 4 | $7.9B | $1.4B |
| Year 5 | $8.7B | $1.5B |
What the street says
A high-quality medical device company; the debate is how much weight-loss drugs matter.
Comparable companies: A · IDXX · EW · DXCM · ABT · BIIB · SNY · SYK
Open the interactive model, price chart and sensitivity grid →